Ferroptosis Regulator Information

General Information of the Ferroptosis Regulator (ID: REG40048)
Regulator Name Circ_CMTM3 (circRNA)
Synonyms
Circ_CMTM3
    Click to Show/Hide
Gene Name Circ_CMTM3
Regulator Type circRNA
Full List of the Ferroptosis Target of This Regulator and Corresponding Disease/Drug Response(s)
Circ_CMTM3 can regulate the following target(s), and cause disease/drug response(s). You can browse detail information of target(s) or disease/drug response(s).
Browse Target
Browse Disease
Unspecific Target [Unspecific Target]
In total 1 item(s) under this target
Experiment 1 Reporting the Ferroptosis Target of This Regulator [1]
Responsed Disease Hepatocellular carcinoma ICD-11: 2C12
 Disease Info 
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Cell Process Cell ferroptosis
Cell proliferation
In Vitro Model
 Huh-7 cells Hepatocellular carcinoma Homo sapiens CVCL_0336
HCCLM3 cells Adult hepatocellular carcinoma Homo sapiens CVCL_6832
THLE-2 cells Normal Homo sapiens CVCL_3803
Hep 3B2.1-7 cells Hepatocellular carcinoma Homo sapiens CVCL_0326
SK-HEP-1 cells Liver and intrahepatic bile duct epithelial neoplasm Homo sapiens CVCL_0525
Hep-G2 cells Hepatoblastoma Homo sapiens CVCL_0027
In Vivo Model
Six-week-old BALB/c female athymic nude mice (SJA Laboratory Animal Co., Ltd, China) were used to construct the xenograft. The mice were randomly grouped: (1) shNC + vehicle; (2) shNC + Erastin; (3) shWTAP + Erastin; (4) shcircCMTM3 + Erastin. Briefly, HCC cells with stable silenced WTAP and circCMTM3 (2 x 106 in 0.1 mL PBS) were injected into the left flank of the mice subcutaneously. Once the tumor size reached approximately > 60 mm3, mice in the groups (2), (3), and (4) were injected with 15 mg/kg erastin. Erastin was injected twice a day for a period of time.

    Click to Show/Hide
Response regulation CircCMTM3 promoted the carcinogenesis through inhibiting ferroptosis by recruiting IGF2BP1 to increase PARK7 stability in hepatocellular carcinoma (HCC), suggesting that cicrCMTM3 may be an important marker for HCC treatment.
Hepatocellular carcinoma [ICD-11: 2C12]
 Disease Info 
In total 1 item(s) under this disease
Experiment 1 Reporting the Ferroptosis-centered Disease Response [1]
Target Regulator Circ_CMTM3 (circRNA) circRNA
 Regulator Info 
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Cell Process Cell ferroptosis
Cell proliferation
In Vitro Model
 Huh-7 cells Hepatocellular carcinoma Homo sapiens CVCL_0336
HCCLM3 cells Adult hepatocellular carcinoma Homo sapiens CVCL_6832
THLE-2 cells Normal Homo sapiens CVCL_3803
Hep 3B2.1-7 cells Hepatocellular carcinoma Homo sapiens CVCL_0326
SK-HEP-1 cells Liver and intrahepatic bile duct epithelial neoplasm Homo sapiens CVCL_0525
Hep-G2 cells Hepatoblastoma Homo sapiens CVCL_0027
In Vivo Model
Six-week-old BALB/c female athymic nude mice (SJA Laboratory Animal Co., Ltd, China) were used to construct the xenograft. The mice were randomly grouped: (1) shNC + vehicle; (2) shNC + Erastin; (3) shWTAP + Erastin; (4) shcircCMTM3 + Erastin. Briefly, HCC cells with stable silenced WTAP and circCMTM3 (2 x 106 in 0.1 mL PBS) were injected into the left flank of the mice subcutaneously. Once the tumor size reached approximately > 60 mm3, mice in the groups (2), (3), and (4) were injected with 15 mg/kg erastin. Erastin was injected twice a day for a period of time.

    Click to Show/Hide
Response regulation CircCMTM3 promoted the carcinogenesis through inhibiting ferroptosis by recruiting IGF2BP1 to increase PARK7 stability in hepatocellular carcinoma (HCC), suggesting that cicrCMTM3 may be an important marker for HCC treatment.
References
Ref 1 WTAP-mediated m6A modification on circCMTM3 inhibits hepatocellular carcinoma ferroptosis by recruiting IGF2BP1 to increase PARK7 stability. Dig Liver Dis. 2023 Jul;55(7):967-981. doi: 10.1016/j.dld.2022.12.005. Epub 2022 Dec 30.